Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

680 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comment on: Gao B, Lu Q, Wan R, Wang Z, Yang Y, Chen Z, Wang Z. "Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials". Naunyn Schmiedebergs Arch Pharmacol. 2021 Apr;394(4):819-828. Epublished November 2020.
Barash S, Ramirez Campos V, Ning X, Driessen MT, Krasenbaum LJ, Carr K, Cohen JM. Barash S, et al. Among authors: carr k. Naunyn Schmiedebergs Arch Pharmacol. 2021 Nov;394(11):2343-2346. doi: 10.1007/s00210-021-02156-5. Epub 2021 Sep 28. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 34581836 Free PMC article.
Commentary: Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide's motor-stimulating and prosecretory function in the intestine.
Mackenzie KD, Ortega M, Kessler Y, Campos VR, Krasenbaum LJ, Carr K, Ning X, Stratton J. Mackenzie KD, et al. Among authors: carr k. Front Physiol. 2022 Nov 29;13:1067274. doi: 10.3389/fphys.2022.1067274. eCollection 2022. Front Physiol. 2022. PMID: 36523559 Free PMC article.
Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response.
Buse DC, Krasenbaum LJ, Seminerio MJ, Packnett ER, Carr K, Ortega M, Driessen MT. Buse DC, et al. Among authors: carr k. Pain Ther. 2024 Jun;13(3):511-532. doi: 10.1007/s40122-024-00583-9. Epub 2024 Mar 12. Pain Ther. 2024. PMID: 38472655 Free PMC article.
US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review.
Eugeni P, Rooney ME, Saikali NP, Niu Z, Driessen MT, Krasenbaum LJ, Carr K, Seminerio MJ, McVige JW. Eugeni P, et al. Among authors: carr k. Adv Ther. 2025 Jan 8. doi: 10.1007/s12325-024-03063-w. Online ahead of print. Adv Ther. 2025. PMID: 39775579
Cognitive Function in a Randomized Trial of Evolocumab.
Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Giugliano RP, et al. N Engl J Med. 2017 Aug 17;377(7):633-643. doi: 10.1056/NEJMoa1701131. N Engl J Med. 2017. PMID: 28813214 Free article. Clinical Trial.
680 results